AWM
CUE icon

Accel Wealth Management’s Cue Biopharma CUE Stock Holding History

Accel Wealth Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11
Closed -$1.14K – 316
2023
Q1 		$1.14K Hold
11
– – ﹤0.01% 1157
2022
Q4 		$906 Hold
11
– – ﹤0.01% 976
2022
Q3 		$1K Sell
11
-132
-92% -$11.4K ﹤0.01% 982
2022
Q2 		$11K Buy
+143
New +$16.7K 0.01% 685

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Accel Wealth Management's CUE Position: Q2 2023 in Review

Accel Wealth Management sold out of Cue Biopharma (CUE) in Q2 2023, closing a stake of 11 shares — an estimated $1.14K sold.

Accel Wealth Management first reported a position in CUE in Q2 2022 and held it in 4 quarters. The position peaked at $11K in Q2 2022. 78 funds tracked by Wall St. Rank hold CUE as of Q2 2023.

  • Accel Wealth Management reported no remaining Cue Biopharma position as of Q2 2023 after selling out during the quarter.
  • Accel Wealth Management sold 11 Cue Biopharma shares in Q2 2023, an estimated $1.14K.
  • Accel Wealth Management first reported a position in Cue Biopharma in Q2 2022 and held it in 4 quarters.
  • Accel Wealth Management's Cue Biopharma position peaked at $11K in Q2 2022.
  • 78 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2023.

Based on Accel Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.